TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01268501

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lotrafilcon B multifocal contact lens
Description: Commercially marketed, silicone hydrogel, multifocal, soft contact lenses FDA-approved for up to 4 weeks recommended replacement schedule and up to 6 nights of extended (overnight) wear.
Study: NCT03905876

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire
Description: Questionnaire to evaluate psychological experience
Study: NCT02321072

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Study: NCT02362555

Intervention type: OTHER
Intervention: no intervention was used in this observational study

Intervention type: OTHER
Intervention: no intervention was used in this observational study
Study: NCT00950963

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone Counseling
Description: Patient were contacted on a periodic basis via telephone to address there diabetes care.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Clinical Care
Description: Patients in the usual care or control group were contacted at the beginning of the study only if they had not had an LDL level in the previous 12 months. A letter requesting their presentation for an LDL test was sent to their last known address along with a lab slip and a reminder to schedule an appointment with their PCP for follow-up of results. No additional contact was made with them by the study nurses.
Study: NCT01992523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor mashed pills
Description: The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In all case before the end of the PCI (percutaneous coronary intervention) . In the case of vomit in the first hour after drug loading dose a new reduced loading dose will be administered (90 mg Ticagrelor). Mashed pills administration will be prepared placing 2 ticagrelor pills in a mortar and mashing for 60 seconds using a pestle. The total contents of the mortar will be transferred to the dosing cup, 50 mL of purify water will be added, and the suspension mixed up before drinking. Afterwards, 100 mL of purify water will be administered to the patient.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor integral pills
Description: The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In all case before the end of the PCI (percutaneous coronary intervention) . In the case of vomit in the first hour after drug loading dose a new reduced loading dose will be administered (90 mg Ticagrelor).
Study: NCT00345943

Intervention type: OTHER
Intervention: MRI
Description: Magnetic Resonance Imaging scans

Intervention type: OTHER
Intervention: MRI
Description: Magnetic Resonance Imaging scans

Intervention type: BEHAVIORAL
Intervention: Neuropsychological Testing
Description: Neuropsychological tests
Study: NCT01526005

Intervention type: DRUG
Intervention: Transdermal Nicotine Patch
Description: 1 patch per day; dosages of 21 mg/day for 4 weeks, 14 mg/day for 2 weeks, and 7 mg/day for 2 weeks; 8 weeks total

Intervention type: DRUG
Intervention: Transdermal Placebo Patch
Description: 1 patch per day; 8 weeks total
Study: NCT02297646

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Endurance Training

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Endurance Training
Study: NCT01882192

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family physical activity planning
Description: This material will include skill training content (workbook how to plan for family physical activity) and practical material to create a plan (i.e., a colourful dry erase wall calendar for family activities with fridge magnets). The skill training material for planning is based on several streams of prior work in the adult physical activity literature. Families were instructed to plan for when, where, how, and what physical activity will be performed commensurate with the creation of implementation intentions/action planning. The workbook, however, also focuses on problem solving barriers to physical activity which is more akin to coping planning and traditional goal setting.
Study: NCT00618904

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics - Lactobacillus and bifidobacterium
Description: Probiotics administered bid for 6 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered bid for 6 weeks.
Study: NCT02833818

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CAKE-intervention
Description: Increased protein and energy supplementation and conversations

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: CAKE-control
Description: nutrition according to established procedures
Study: NCT02151799

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Abdominoplasty and liposuction
Study: NCT03794297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib Dimethyl Sulfoxide
Description: Given PO
Study: NCT02251184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aggrenox

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dipyridamole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole
Study: NCT01023620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Participants will take oral Pioglitazone 45 mg daily for 16 weeks.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Observation
Description: Participants will be observed for 16 weeks but will not receive drug
Study: NCT02642328

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HIIT Training
Description: Circuit of high intensity interval training (HIIT) with Strength and Power Exercises for 4 minutes (20 sec of stimulus / 10 sec rest)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Continuous aerobic exercise at 65% of VO2Max
Study: NCT00814970

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Complete SE Vascular Stent System
Description: Complete SE Vascular Stent System in the treatment of de novo and/or restenotic lesions or occlusions in the Superficial Femoral Artery (SFA) and/or the Proximal Popliteal Artery (PPA) in subjects with symptomatic Peripheral Artery Disease (PAD).
Study: NCT02613975

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: positonal device
Description: positional device detects prone positional and will vibrate to cause patient to lie laterally

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: positonal device
Description: positional device detects prone positional and will vibrate to cause patient to lie laterally
Study: NCT03673449

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SilkBridge
Description: SilkBridge is a biocompatible silk fibroin-based scaffold, which recruits the patients' own cells to remodel or regenerate the nerve, without pre-seeding of the scaffold nor biological/chemical treatments.
Study: NCT02632981

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: nonsurgical periodontal treatment
Description: Scaling and root planning under local anaesthesia, in a total of four clinical visits Oral hygiene instructions including the modified Bass technique, regular toothpaste, and an appropriate interdental cleaning device with dental floss and interdental brush.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Gingival crevicular fluid and saliva collection
Description: GCF collection with filter paper (Periopaper) using the intracrevicular method. Patients' mouths were rinsed with distilled water, and unstimulated salivary samples were collected by patients expectorating into disposable tubes.
Study: NCT01572558

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Appendectomy
Description: Standard surgical treatment, normally laparoscopic appendectomy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conservative, non-surgical treatment
Description: Non-surgical treatment, intravenous and oral antibiotics. Meropenem and Metronidazol will be used as intravenous antibiotics, Ciprofloxacin and Metronidazol will be used as oral antibiotics.
Study: NCT02298920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0914
Description: Radiolabelled AZD0914 for study of absorption, disposition, metabolism, and excretion in healthy volunteers.
Study: NCT03462303

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Sham tDCS and tyrosine depleted drink
Description: Transcranial direct current stimulation (sham) of the dlPFC in combination with a tyrosine and phenylalanine free product.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Anodal tDCS and tyrosine depleted drink
Description: Transcranial direct current stimulation (anodal) of the dlPFC in combination with a tyrosine and phenylalanine free product.

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Sham tDCS and balanced drink
Description: Transcranial direct current stimulation (sham) of the dlPFC in combination with a drink containing both tyrosine and phenylalanine.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Anodal tDCS and balanced drink
Description: Transcranial direct current stimulation (anodal) of the dlPFC in combination with a drink containing both tyrosine and phenylalanine.
Study: NCT00933972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4998452
Description: 20mg po single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4998452
Description: 20mg po single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4998452
Description: 20mg po single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4998452
Description: 20mg po single dose
Study: NCT03198572

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: Lifestyle intervention is consisted of diet control and aerobic exercise. calorie restriction: to subtract 500 kcal from daily calorie intake aerobic exercise: medium intensity aerobic exercise for more than 150 min per week with heart rate around 50-70% of the maximal heart rate.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Lifestyle intervention
Description: Lifestyle intervention is consisted of diet control and aerobic exercise. calorie restriction: to subtract 500 kcal from daily calorie intake aerobic exercise: medium intensity aerobic exercise for more than 150 min per week with heart rate around 50-70% of the maximal heart rate.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo tablets 0.5 tid, 30 minutes before each meal, for 48weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berberine
Description: Berberine tablets 0.5 tid, 30 minutes before each meal, for 48weeks
Study: NCT00101595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Tablets, Oral, 70 mg, twice daily, Until disease progression or untolerable toxicity, switch to the roll-over study or study closure
Study: NCT00793091

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: C-KAD Ophthalmic Solution
Description: 4 drops applied daily for 120 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 drops applied daily for 120 days
Study: NCT04462445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Study: NCT03439553

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ads display with target websites
Description: Ads are shown, but users are referred to control websites.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Ads display with control websites
Description: Ads are shown, but users are referred to control websites.
Study: NCT03743623

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurocytotron
Description: Neurocytotron utilizes a combination of instantaneous magnetic field and low-spectrum radiofrequency waves for therapeutic purpose. Its working principle is based on the theory of magnetic resonance.
Study: NCT03368352

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Dietary supplement melatonin

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Hypoxia
Description: Sleep in a hypoxic tent simulating high altitude
Study: NCT00420342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drospirenone/17ß-estradiol (Angeliq, BAY86-4891)
Description: SH K 00641 A -Active study medication encapsulated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drospirenone/17ß-estradiol (Angeliq, BAY86-4891)
Description: SH K 00641 B - Active study medication encapsulated tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SH K 00641 C - Medroxyprogesterone acetate / conjugated equine (Prempro TM)
Description: Active control encapsulated tablet
Study: NCT03743623

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Same treatment procedures without being actually exposed to electromagnetic waves and magnetic field
Study: NCT02661893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42847922
Description: A single oral dose of 40 milligram (mg) (=2\*20 mg) dose of JNJ42847922 on Day 1, Day 5 and Day 12.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Oral dose of rifampin 600 mg (2\*300 mg) on Day 5 and once daily dosing of rifampin with an oral dose of rifampin 600 mg (2\*300 mg) on Days 5 to 12.
Study: NCT01546207

Intervention type: PROCEDURE
Group type: OTHER
Intervention: catheter-based ablation
Description: specific electrophysiological and mapping techniques of activation and entrainment mapping during ongoing VT. Substrate mapping and ablation (substrate modification.) catheter ablation - a medical procedure used to treat some types of arrhythmia
Study: NCT04503902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donafenib Tosilate Tablets
Description: In the dose exploration phase (phase I)，three doses of Donafenib tosylate tablets \[100 mg once a day (QD); 100 mg twice a day (BID); 200 mg, BID\] will be explored. In the dose expansion phase (phase II), patients will be treated at the recommended dose for phase 2(RP2D).The RP2D will be determined by the dose escalation study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab Injection
Description: JS001 will be administrated by intravenous (i.v.) infusion once every 21 days
Study: NCT05382624

Intervention type: PROCEDURE
Intervention: Abdominal circumference was measured at the umbilical level in the standing position at the end of a normal expiration.
Description: The operation time (the time from the beginning of the surgical incision until the end of surgery), anesthetic complications, such as nausea or vomiting, the number of patients requiring ephedrine and atropine, the total amount of intravenous fluid used, and the total amount of ephedrine used during surgery were recorded.
Study: NCT01251601

Intervention type: OTHER
Intervention: Pharmacokinetics
Description: Up to three 12 hour PK sampling sessions, one in the second trimester, one in the third trimester and one post partum
Study: NCT04678245

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Above the Influence-Vaping (ATI-V)
Description: Peer-nominated 8th grade and 9th grade Peer Leaders (PL) will be trained in a half day ATI-V training. Adult Advisors (AA) will attend a half day ATI-V AA training and the PL training. The training day builds leadership skills in the PLs, develops skills for rising above pressure to vape including identification of personal reasons to rise, identification of healthy support people, teaching accurate use statistics, and sharing stories of prior success in rising above negative pressures. The ATI-V team of PLs and AAs then will run four interactive messaging campaigns to reach the rest of the student body. These four campaigns are (1) Introduction to ATI-V and My Reasons to Rise (2) Gain and Loss (3) Who's Got My Back (4) The Facts. Each campaign features a portion in which PLs model healthy norms and behaviors, and a second portion in which all the rest of the students engage in an interactive component to build and demonstrate the target skill.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Above the Influence-Vaping (ATI-V)
Description: Peer-nominated 8th grade and 9th grade Peer Leaders (PL) will be trained in a half day ATI-V training. Adult Advisors (AA) will attend a half day ATI-V AA training and the PL training. The training day builds leadership skills in the PLs, develops skills for rising above pressure to vape including identification of personal reasons to rise, identification of healthy support people, teaching accurate use statistics, and sharing stories of prior success in rising above negative pressures. The ATI-V team of PLs and AAs then will run four interactive messaging campaigns to reach the rest of the student body. These four campaigns are (1) Introduction to ATI-V and My Reasons to Rise (2) Gain and Loss (3) Who's Got My Back (4) The Facts. Each campaign features a portion in which PLs model healthy norms and behaviors, and a second portion in which all the rest of the students engage in an interactive component to build and demonstrate the target skill.
Study: NCT04091854

Intervention type: DRUG
Intervention: HMS5552
Description: To observe the progress of diabetes mellitus after 52 or 28 weeks of HMS5552 treatment for type 2 diabetes mellitus
Study: NCT02601469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSXS
Description: twice daily for 28 days
Study: NCT01162512

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical activity
Description: physical activity counseling sessions will occur by telephone weekly for 2 months
Study: NCT00530244

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (DHA)
Description: Infant formula with 0.96% of fatty acids as DHA

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Standard formula (Enfamil)
Description: This is a standard, commercially available infant formula.
Study: NCT00899054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P276-00
Description: P276-00 will be administered at different dose levels: level 1: 100 mg/m2/day dose level 2: 140 mg/m2/day dose level 3: 185 mg/m2/day to be given from day 1 to day 5 every 21 days for 2 cycle. P276-00 will be administered as intravenous infusion in 200 ml 5% Dextrose over 30 min from days 1 to 5 per 21 day cycle for two cycles.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External beam radiotherapy (EBRT)
Description: All subjects will receive external beam radiotherapy (EBRT)by using standard conventional fractionation i.e. 2 Gy per day for 5 days a week for a total radiation dose of 60 Gy over 6 weeks followed by upto 10 additional Gy if required.
Study: NCT02079545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirukumab (IV infusion)
Description: Participants will receive a single IV infusion of 100 mg sirukumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirukumab (SC injection with PFS-U)
Description: Participants will receive a single SC injection of 50 mg sirukumab with PFS-U.
Study: NCT01855945

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Swine Influenza
Description: Comparison of different dosages of vaccines

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Swine Influenza
Description: Comparison of different dosages of vaccines

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Swine Influenza
Description: Comparison of different dosages of vaccines
Study: NCT00550290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefazolin PostOperatively
Description: Cefazolin 1 gram IV every 8 hours for a total of 3 doses. Patients in both arms will receive an initial pre-operative 2 gram dose of Cefazolin within 30 minutes prior to incision. In penicillin/cephalosporin allergic patients, the substitute of Clindamycin 900 mg IV q 8 hrs will be used.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin Preoperatively
Description: Patients in active comparator arm will receive an initial pre-operative 2 gram does of Cefazolin within 30 minutes prior to incision. In penicillin/cephalosporin allergic patients, the substitute of Clindamycin 900 mg IV will be used.
Study: NCT01201304

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard exposure
Description: Three 60-second trials of hyperventilation, each followed by diaphragmatic breathing, cognitive reappraisal, and prolonged rest until body sensations have subsided.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced exposure
Description: Three 60-second trials of hyperventilation, each followed by a 15-second rest period and cognitive reappraisal.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive exposure
Description: Minimum of eight 60-second hyperventilation trials, each followed by 15-second rest period and cognitive reappraisal. Trials continue until participants rate the probability that their most feared outcome will occur as less than 5% on a 0% to 100% scale.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Expressive writing
Description: Individuals randomized to the expressive writing control group will receive a rationale for why writing about emotional issues helps resolve the fear of body sensations. These participants will then be asked to spend the next 25 minutes writing about past emotional issues. Participant writings are confidential and will not be viewed by the experimenter.
Study: NCT00111436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Enbrel 50 mg once weekly or 50 mg twice weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Enbrel 50 mg once weekly or 50 mg twice weekly
Study: NCT01843205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methamphetamine
Description: The pharmacodynamic effects of methamphetamine will be determined during placebo and buspirone maintenance.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methamphetamine
Description: The pharmacodynamic effects of methamphetamine will be determined during placebo and buspirone maintenance.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The pharmacodynamic effects of placebo methamphetamine will be determined during placebo and buspirone maintenance.
Study: NCT00345943

Intervention type: BEHAVIORAL
Intervention: Neuropsychological Testing
Description: Neuropsychological tests
Study: NCT01799525

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypercapnia by reduction of respiratory volume
Description: By reduction of the respiratory volume, PaCO2 is raised while paO2 is kept constant by modulation of the oxygen supply through the respirator,